The pandemic was a clear catalyst for the rise of decentralized clinical trials (DCTs). But it may come as a surprise to some that this shift was already gaining momentum in the years prior due to advancements in technology. Telemedicine platforms, electronic data capture[...]

Respiratory medicine is continuously evolving, with new advancements taking shape to support progress and better outcomes every day. We recently discussed some of these advancements with Dr. Edward Cordasco, a Remington-Davis (RDI) board-certified physician with over 36 years of[...]

Diversity has always mattered in clinical trials. As the National Institutes of Health (NIH) notes, “people may experience the same disease differently.” With a more diverse pool of clinical trial participants, researchers can better account for these differences and support[...]

Healthy volunteers are a cornerstone of successful clinical trials. Before medications or devices are given to patient groups with a specific condition, interventions on healthy volunteers set a baseline in the early stages of clinical research. These control groups ultimately[...]

The landscape of immunology clinical trials rarely stands still, from breakthroughs in scientific advancements to changing outlooks on trial dynamics and expectations. Dr. Ian Baird, a Remington-Davis (RDI) board-certified infectious disease physician who has conducted 262[...]

Here’s your chance to catch up on a story featuring two #OSUNursing students who #volunteered for a #clinicaltrial with #RemingtonDavis when they contracted #Covid_19. [...]

By Chris Newmarker | July 8, 2020 Clinical research outfit Remington-Davis recently announced that it has launched a dedicated 3,000 ft2 space in Columbus, Ohio for COVID-19 clinical trials. The space includes six private overnight rooms, patient lounge, dedicated laboratory,[...]